Selected article for: "antiviral response and human infection"

Author: Yuan, Lin; Chen, Zhongbin; Song, Shanshan; Wang, Shan; Tian, Chunyan; Xing, Guichun; Chen, Xiaojuan; Xiao, Zhi-Xiong; He, Fuchu; Zhang, Lingqiang
Title: p53 Degradation by a Coronavirus Papain-like Protease Suppresses Type I Interferon Signaling
  • Cord-id: 7c7qkgca
  • Document date: 2015_1_30
  • ID: 7c7qkgca
    Snippet: Infection by human coronaviruses is usually characterized by rampant viral replication and severe immunopathology in host cells. Recently, the coronavirus papain-like proteases (PLPs) have been identified as suppressors of the innate immune response. However, the molecular mechanism of this inhibition remains unclear. Here, we provide evidence that PLP2, a catalytic domain of the nonstructural protein 3 of human coronavirus NL63 (HCoV-NL63), deubiquitinates and stabilizes the cellular oncoprotei
    Document: Infection by human coronaviruses is usually characterized by rampant viral replication and severe immunopathology in host cells. Recently, the coronavirus papain-like proteases (PLPs) have been identified as suppressors of the innate immune response. However, the molecular mechanism of this inhibition remains unclear. Here, we provide evidence that PLP2, a catalytic domain of the nonstructural protein 3 of human coronavirus NL63 (HCoV-NL63), deubiquitinates and stabilizes the cellular oncoprotein MDM2 and induces the proteasomal degradation of p53. Meanwhile, we identify IRF7 (interferon regulatory factor 7) as a bona fide target gene of p53 to mediate the p53-directed production of type I interferon and the innate immune response. By promoting p53 degradation, PLP2 inhibits the p53-mediated antiviral response and apoptosis to ensure viral growth in infected cells. Thus, our study reveals that coronavirus engages PLPs to escape from the innate antiviral response of the host by inhibiting p53-IRF7-IFNβ signaling.

    Search related documents:
    Co phrase search for related documents
    • absence presence and acute severe: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • absence presence and acute severe respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • absence presence and lps treatment: 1, 2
    • absence presence and luciferase activity: 1, 2, 3, 4, 5
    • absence presence and luciferase assay: 1
    • absence presence and luciferase gene: 1, 2, 3, 4
    • absence presence and luciferase reporter: 1, 2, 3, 4, 5
    • absence presence and lung adenocarcinoma: 1, 2, 3
    • activity inhibit and acute severe: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • activity inhibit and acute severe respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • activity inhibit and luciferase activity: 1, 2, 3
    • activity inhibit and luciferase assay: 1, 2, 3
    • activity inhibit and luciferase gene: 1
    • activity inhibit and luciferase reporter: 1, 2, 3, 4, 5
    • activity inhibit and lung adenocarcinoma: 1
    • acute severe and low dosage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute severe and lps induce: 1, 2, 3
    • acute severe and lps induce production: 1
    • acute severe and lps treatment: 1, 2, 3, 4, 5, 6